Personalized briefing
Discovery of the day · Diabetes
Compartment-specific cAMP dysfunction in diabetic cardiomyopathy in hiPSC-derived cardiomyocytes: therapeutic potential of fibroblast growth factor 1
Dear Dr. Vijay Viswanathan, this is your personalized scientific intelligence briefing — curated for your work in Diabetes.
Key finding
Medicine · Diabetes
Discovery of the day
This study identifies compartment-specific cyclic AMP (cAMP) signaling dysfunction as a key mechanistic driver of diabetic cardiomyopathy using human induced pluripotent stem cell-derived cardiomyocytes. The researchers demonstrated that diabetic conditions disrupt localized cAMP microdomains, impairing β-adrenergic responsiveness and contractile function. Fibroblast growth factor 1 (FGF1) restored compartmentalized cAMP signaling and improved cardiomyocyte function, revealing a novel therapeutic target for managing diabetes-related cardiac complications. This finding is directly relevant to clinical diabetes practice, as it opens a potential pathway for FGF1-based interventions that could mitigate cardiovascular morbidity in patients with diabetes — expanding beyond glycemic control to directly address diabetic complications that are leading causes of mortality.
Novelty
92%
Rigor
85%
Significance
90%
Validity
82%
Clarity
88%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
